Detalhe da pesquisa
1.
Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball.
Cell
; 168(4): 575-578, 2017 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28187280
2.
All is not lost: learning from 9p21 loss in cancer.
Trends Immunol
; 43(5): 379-390, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379580
3.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 25(5): 572-587, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561010
4.
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study.
Br J Cancer
; 130(12): 1936-1942, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38714747
5.
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.
Cancer Immunol Immunother
; 73(5): 89, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554156
6.
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
Br J Cancer
; 129(4): 612-619, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37419999
7.
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
Oncologist
; 28(12): e1209-e1218, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597246
8.
Precision cancer medicine: Concepts, current practice, and future developments.
J Intern Med
; 294(4): 455-481, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37641393
9.
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 41(3): 380-390, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040046
10.
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Br J Clin Pharmacol
; 89(5): 1601-1616, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454221
11.
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE.
Br J Cancer
; 127(9): 1629-1635, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36008705
12.
Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.
Oncologist
; 27(5): 352-362, 2022 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285488
13.
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
Oncologist
; 27(3): e286-e293, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274718
14.
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
Cancer
; 127(10): 1620-1629, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33496357
15.
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).
Br J Cancer
; 124(9): 1543-1551, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33750907
16.
Small molecules, big impact: 20 years of targeted therapy in oncology.
Lancet
; 395(10229): 1078-1088, 2020 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32222192
17.
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Invest New Drugs
; 39(6): 1587-1597, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180037
18.
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Cancer
; 126(22): 4936-4947, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32870522
19.
Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Cancer
; 126(15): 3426-3437, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32478895
20.
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
Cancer
; 126(7): 1550-1558, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914209